Abstract. Increasing evidence suggests that the failure of lung cancer treatment may occur as a result of tumor invasion and metastasis. Signal transducer and activator of transcription 3 (STAT3), an epithelial-mesenchymal transition-inducing transcription factor, is a key signaling molecule involved in the proliferation, apoptosis, invasion and metastasis of tumor cells. Sinomenine is an alkaloid compound with an antineoplastic potential against a variety of cancer cells. The aim of the present study was to assess the antitumor mechanisms of sinomenine in the A549 human lung cancer cell line. The results demonstrated that sinomenine manifested dose-dependent cytotoxicity and induced apoptosis in A549 cells. The protein expression of Janus kinase 2, STAT3, phosphorylated-STAT3, Snail, N-cadherin and vimentin decreased in sinomenine-treated cells, while E-cadherin protein expression increased. The regulation of STAT3, N-cadherin and E-cadherin by sinomenine was further confirmed by reverse transcription-quantitative polymerase chain reaction and immunofluorescent staining. It was demonstrated that sinomenine exerts inhibitory effects on A549 human lung cancer cell invasion, possibly through the inhibition of STAT3 signaling. These results provide a novel insight into the role of sinomenine in the treatment of non-small cell lung cancer.
Introduction
Lung cancer is one of the most common types of malignant tumor with a high mortality (1) . Although surgical resection is currently the optimal treatment for lung cancer, treatment of this disease remains challenging as patients have not demonstrated long-term clinical benefits (2) . According to the recent International Database, following complete resection of lung cancer, the 5-year survival rate of patients with lung cancer is 73% for pathological stage IA, 58% for stage IB, 46% for stage IIA, 36% for stage IIB and 24% for stage IIIA (3) . The failure of combined chemotherapy and surgical resection is primarily attributed to cancer metastasis and invasion (4, 5) . Therefore, it is necessary to seek more effective anticancer agents targeting tumor invasion and metastasis.
Plants and other natural products are important chemical sources for chemotherapy (6, 7) . Sinomenine is an active compound of the plant Sinomenium acutum, which has been widely used as traditional medicine in the treatment of various rheumatic diseases in China (8) . It has been demonstrated that sinomenine has a number of pharmacological activities, including anti-inflammatory, antirheumatic, antiangiogenic and immunosuppressive effects (9, 10) . Furthermore, there is strong evidence to suggest that sinomenine has antineoplastic potential against a variety of cancer cells, including synovial sarcoma, lung cancer and hepatocellular carcinoma (11) (12) (13) .
Chronic inflammation is undeniably a contributing factor in tumour proliferation, survival, angiogenesis and metastasis (14) (15) (16) . To date, the majority of studies investigating inflammation and cancer have focused on the regulatory network dominated by nuclear factor (NF)-κB and signal transducer and activator of transcription 3 (STAT3) (17) (18) (19) . STAT3 is a key molecule in the promotion of tumorigenesis, functioning via chronic inflammation, and also in the process of cancer-related inflammation, which is able to regulate the biological behavior of cancer and immune cells through mediation of extracellular signaling of inflammatory factors (18) . Given the roles of STAT3 in chronic inflammation, and the regulation of the initiation and resolution of epithelial-mesenchymal transition (EMT) in malignant cells (20, 21) , decreasing or blocking its activity may suppress malignant conversion. The present study hypothesized that Annexin V staining. Apoptosis was determined using an fluorescein isothiocyanate (FITC) Annexin V apoptosis DTEC KIT (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. First, A549 cells were incubated with sinomenine for 24 and 48 h. The cells were collected and washed twice with cold PBS and then resuspended in 1X Binding Buffer at a concentration of 1x10 6 cells/ml. Subsequently, 100 µl of the suspension (1x10 5 cells) was transferred to a 5 ml culture tube, and 5 µl FITC-conjugated Annexin V with 10 µl propidium iodide (PI) were added. The cells were gently vortexed and incubated for 15 min at 25˚C in the dark. Finally, 400 µl of 1X Binding Buffer was added to each tube and analyzed using the FACSCalibur™ flow cytometer and CellQuest Pro software version 6.0 (BD Biosciences) within 1 h.
Western blotting. Western blotting was performed as previously described (22) . Following treatment with sinomenine for 48 h, A549 cells were lysed in radioimmunoprecipitation assay lysis buffer (Applygen Technologies, Inc., Beijing, China). The cell debris was removed by centrifugation (15 min, 12,000 x g; Eppendorf, Hamburg, Germany), and the supernatant was stored at -80˚C. Protein concentrations were estimated using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.).
Cell lysates (20 µg per lane) were subjected to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (Marker: Amresco, LLC, Solon, OH, USA; Electrophoretic and transfer equipment: Bio-Rad Laboratories, Inc., Hercules, CA, USA) and subsequently transferred to nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% skimmed milk, or bovine serum albumin (BSA; Vivantis Technologies, Oceanside, CA, USA) for phosphorylated proteins, in Tris-buffered saline with Tween 20 (50 mM Tris, 150 mM NaCl and 0.05% Tween 20), and serially incubated with primary antibodies at 4˚C overnight and secondary antibodies for 1 h at room temperature. The antibodies used were as follows: Rabbit monoclonal anti-JAK2 (dilution, 1:1,000; catalog no., 3230), anti-STAT3 (dilution, 1:1,000; catalog no., 12640), anti-phosphorylated (p)-STAT3 (dilution, 1:1,000; catalog no., 9145), anti-β-actin (dilution, 1:1,000; catalog no., 4970), anti-Snail (dilution, 1:1,000; catalog no., 3879), anti-vimentin (dilution, 1:1,000; catalog no., 5741), anti-E-cadherin (dilution, 1:1,000; catalog no., 3195) (Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-N-cadherin (1:1,000; catalog no., 180224; Thermo Fisher Scientific, Inc.) antibodies, and horseradish peroxidase-linked anti-rabbit (catalog no., 7054) or anti-mouse (catalog no., 7076) immunoglobulin (Ig)G antibodies (dilution, 1:2,000; Cell Signaling Technology, Inc.). The bands were visualized using a chemiluminescence reagent (Applygen Technologies, Inc.) and recorded with a ChemiDoc™ XRS imaging system (Bio-Rad Laboratories, Inc.). The band densities were quantified using β-actin as a loading control, and analyzed using Image J (https://imagej.nih.gov/ij/).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The extraction of 5 mg total RNA from the A549 cells was performed using TRIzol ® reagent (Thermo Fisher Scientific, Inc.). The concentration and purity of the extracted RNA were determined with a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, Inc.), while electrophoresis was conducted to verify its integrity. A 2% agarose gel was used, the markers were supplied by Amresco, LLC, and the electrophoretic tank and visualization equipment were from Beyotime Institute of Biotechnology (Jiangsu, China).
To prepare the reaction master mix, 2 ml 10X RT buffer, 4 ml 25 mM MgCl 2 , 2 ml 0.1 M dithiothreitol and 1 ml RNAaseOUT were combined. The reaction mixture was added to the RNA/primer mixture, mixed briefly, and then incubated at room temperature for 2 min. SuperScript II RT (1 ml; 50 units) was added each tube, mixed and incubated at 25˚C for 10 min. Tubes were incubated at 42˚C for 50 min, heat inactivated at 70˚C for 15 min, and then chilled on ice. RNase H (1 ml) was added and incubated at 37˚C for 20 min. The first strand of complementary DNA (cDNA) was synthesized by RT using the High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific, Inc.) stored at -20˚C until use. qPCR was performed using TaqMan ® Gene Expression Master Mix (Thermo Fisher Scientific, Inc.), template cDNA and primers. The primers were as follows: STAT3-RT5, 5'-CAT CAT GGG CTT TAT CAG TAA GGA-3' and STAT3-RT3, 5'-GTC AAT GGT ATT GCT GCA GGT CGT-3'; E-cadherin-RT5, 5'-CCC ACC ACG TAC AAG GGT C-3' and E-cadherin-RT3, 5'-CTG GGG TAT TGG GGG CAT C-3'; N-cadherin-RT5, 5'-GCG GAG AGG AAG ACC AGG A-3' and N-cadherin-RT3, 5'-TAG TTG GGC TCC GAG TGC AT-3'; GAPDH forward, 5'-TGC ACC ACC AAC TGC TTA GC-3 and reverse, 5'-GGC ATG GAC TGT GGT CAT GAG-3'.
To prepare the mixture, 12.5 ml SYBR Green Mix (2X), 0.2 ml cDNA, 1 ml primer pair mix (5 pmol/ml each primer) and 11.3 ml H 2 O were combined. The total volume of each combined reaction mixture was 20 µl. Gene-specific, fluorogenic RT-qPCR for STAT3, E-cadherin, N-cadherin and glyceraldehyde 3-phosphate dehydrogenase was performed using (23) . The ABI Prism SDS 7300 (Thermo Fisher Scientific, Inc.) was used for quantification and the results were viewed and analyzed with Applied Biosystems 7500 Fast system (Thermo Fisher Scientific, Inc.). The assay was repeated 3 times.
Immunofluorescence. A549 cells were treated with 1.0 mM sinomenine for 24 h and then fixed in 4% paraformaldehyde (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) for 20 min at room temperature. The samples were washed 2 times in phosphate-buffered saline (PBS) to remove residual paraformaldehyde. Cells were permeabilized with 0.1% Triton X-100 made in PBS solution for 15 min, and then washed 3 times with PBS. Subsequent to blocking with 2% BSA for 1 h, cells were washed with PBS and BSA prior to being incubated with anti-STAT3 (1:500), anti-E-cadherin (1:500), anti-N-cadherin (1:500) or anti-vimentin (1:500) primary antibodies overnight at 4˚C. Samples were then washed 5 times with PBS and BSA, followed by incubation with anti-rabbit or anti-mouse IgG secondary antibodies for 1 h at room temperature. Cells were then stained with 4',6-diamidino-2-phenylindole (Santa Cruz Biotechnology, Inc.) and mounted with anti-fading agent. Immunostaining was analyzed using the widefield high-content screening system ImageXpress ® Micro XLS (Molecular Devices, LLC, Sunnyvale, CA, USA).
Statistical analysis.
All experiments were performed three times unless otherwise stated, and data are presented as the mean ± standard deviation. Statistical significance was evaluated using one-way analysis of variance, followed by Fisher's least significant difference test. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA).
Results

Sinomenine reduces A549 cell viability.
To determine the effect of sinomenine on A549 cell viability, cells were treated with various concentrations of sinomenine (0-2 mM) for 24-72 h. The results demonstrated that sinomenine-treated cells exhibited a decreased cell count compared with untreated cells, and the inhibitory effect was dose-dependent (Fig. 1) . As a positive control, cucurbitacin I (0.25 µM) was used, which significantly reduced the number of A549 cells (P<0.05) (Fig. 1) .
Sinomenine induces A549 cell apoptosis. To determine whether the decreased viability of A549 cells following sinomenine treatment occurs as a result of apoptosis, Annexin V-FITC/PI staining was performed. As presented in Fig. 2A , sinomenine induced apoptosis in a dose-and time-dependent manner in A549 cells. The minimum dose of sinomenine required to induce apoptosis was 0.25 mM, while 1 mM sinomenine produced a similar effect to that caused by 0.25 µM cucurbitacin I (Fig. 2B and C) . These results suggest that sinomenine-induced apoptosis may result in decreased cell viability.
Sinomenine regulates the protein expression of JAK2, STAT3
and EMT markers. To investigate the mechanisms underlying the biological effects of sinomenine on A549 cells, the upstream and downstream targets of STAT3 signaling were examined in A549 cells treated with sinomenine for 48 h by western blotting. The results demonstrated that sinomenine and cucurbitacin I downregulated the expression of JAK2, STAT3, p-STAT3, Snail, N-cadherin and vimentin compared with the untreated controls, while E-cadherin expression was upregulated (Fig. 3) .
To further confirm the effect of sinomenine on the STAT3 signal transduction pathway, the messenger (m)RNA expression of STAT3, E-cadherin and N-cadherin was examined by RT-qPCR. The results demonstrated that the mRNA levels of STAT3 and N-cadherin were significantly reduced in the A549 cells following treatment with sinomenine and cucurbitacin I, whereas the level of E-cadherin mRNA was markedly increased (P<0.05) (Fig. 4) . These results indicate that sinomenine may interfere with EMT in A549 cells by reducing the expression levels of the functional targets of the STAT3 signal transduction pathway.
Sinomenine prevents the invasion of A549 cells. To examine whether sinomenine affects the invasion of A549 cells, biomarkers for EMT were examined by immunofluorescence. It was observed that E-cadherin staining under the plasma membrane was significantly increased in the A549 cells treated with sinomenine compared with the untreated control cells, whilst STAT3, N-cadherin and vimentin exhibited a decreased level of staining (Fig. 5) . These results are consistent with the aforementioned western blotting and RT-qPCR data, and strongly suggest that sinomenine is able to attenuate A549 cell invasion through regulation of the STAT3 signaling pathway.
Discussion
The present study observed that sinomenine induced strong cytotoxicity, as indicated by decreased cell viability and apoptosis induction in A549 human lung adenocarcinoma cells. These results are consistent with previous observations in liver, breast and colon tumor cells (13, 24, 25) .
STAT3 is a key transcription factor that is widely expressed in various tissues and cell types, and is primarily activated by the JAK-STAT and mitogen-activated protein kinase signal transduction pathways (26) . Increasing evidence suggests that STAT3 is involved in proliferation, differentiation, invasion, metastasis, angiogenesis and resistance to apoptosis (27) . The reported abnormal upregulation of STAT3 in hematological malignancies and solid tumors, including leukemia, hepatoma, and lung, prostate and breast cancer (28) (29) (30) (31) (32) , indicates that STAT3 is important in the pathogenesis of such tumors. During the process of EMT, epithelial cells lose polarity and gain cell motility, subsequently resulting in cell invasion (36) (37) (38) (39) . A number of studies have reported that EMT is involved in tumor invasion, metastasis and chemoresistance (36, 37) . During tumorigenesis, epithelial-type markers, including β-catenin, E-cadherin and cytokeratin, are typically downregulated, while mesenchymal markers such as N-cadherin and vimentin are upregulated (40) . Therefore, understanding how to effectively restrain the process of EMT is vital for successful treatment of cancer. In the current study, it was observed that sinomenine reversed the protein expression of EMT biomarkers, indicating that sinomenine inhibited cell invasion. In addition, sinomenine may inhibit EMT through the regulation of STAT3 and its downstream target, Snail. It has been demonstrated that STAT3 is required for EMT via upregulation of the downstream gene Snail (41) . Snail is able to directly inhibit the expression of E-cadherin, and subsequently interacts with the COOH-terminal region and the 5'-CAC CTG-3' motif in the E-cadherin promoter sequence to activate EMT (42, 43) . Yadav et al (41) reported that EMT may be induced by Snail, which is activated by the JAK/STAT3 signaling pathway, in head and neck tumor cells, thus resulting in tumor metastasis.
In conclusion, the present study demonstrated that sinomenine affects apoptosis, and inhibits tumor cell death and invasion by suppressing the activation of the STAT3 signaling pathway in A549 cells. To the best of our knowledge, the present study is the first to report that sinomenine is able to reverse EMT changes in A549 cells. These results may aid the understanding of the underlying mechanisms of sinomenine in treating non-small cell lung cancer.
